Compare iShares Semiconductor ETF (SOXX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Semiconductor ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares Semiconductor ETF trades at $506.95 (market cap $44.53B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: iShares Semiconductor ETF is far larger — about 9.1× Travere Therapeutics Inc. Common Stock's market cap, and iShares Semiconductor ETF is more actively traded (8,354,155 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold iShares Semiconductor ETF for 47 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SOXX | TVTX | |
|---|---|---|
Market Cap | $44.53B | $4.88B |
Volume | 8,354,155 | 1,668,577 |
Sector | Sector/Thematic | Health |
52-Week High | $655.01 | $67.52 |
52-Week Low | $268.10 | $26.79 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXX trades at $543.9, down 0.17% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The semiconductor ETF faces mixed sentiment with strong AI-driven earnings growth projections but elevated valuation concerns. Recent news highlights Michael Burry's expanded short position while other analysts point to continued earnings momentum supporting the sector.
The semiconductor sector outlook remains bifurcated between strong AI-driven fundamentals and valuation risks. SOXX's investment case hinges on sustained AI infrastructure demand, though current technical weakness and high multiples relative to broader markets warrant caution. Key risks include sector concentration and potential AI development slowdowns.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
